Medical practice is, by nature, fairly adaptable and customizable to the recipient of care, whether it is the communication with the patient or even the adjustment of the pharmacological therapy administered. For this reason, some say that Personalized Medicine has always existed, as health professionals do everything they possibly can to give the best treatment to the patient in front of them. However, is current medicine truly tailored to the patient? Over the past few years, with the development of new technologies and the emergence of new discoveries in the field of medical research, researchers and clinicians now have access to more information that allows them to make a truly personalized treatment outlining the best strategy for each patient. The new data has the potential to help in new diagnoses, treatments and prevention programmes, but it is crucial to change the paradigm of current medicine, making it increasingly closer to the patient’s daily life. In this module, we will discover which doors will open with this new concept of Personalized Medicine, but also what are its implications.
Saturday | March 12th 2022
Sir Mark Caulfield, MD
Sir Mark Caulfield has made pivotal contributions to life sciences over several decades. At Genomics England, he was instrumental in delivering the 100,000 Genomes Project which has conveyed life-changing results for many patients. He has additionally worked with NHS England in the creation of the National Genomic Test Directory, which offers equitable access for 55 million people to appropriate genomic tests. As Professor of Clinical Pharmacology at Queen Mary University of London, he has also made substantial contributions to the discovery of genes related to cardiovascular health, cancer and rare diseases, with his research changing national and international guidance for high blood pressure. Since 2014, he has been one of the top 200 most highly cited researchers in the world in genomics according to Thomson Reuters.
Edward Perello, MPhil
Edward Perello is an expert in genome editing, biosecurity and strategic communication, having been listed on the “Forbes 30 Under 30 in Tech in Europe“. Perello works with companies and governments to develop technology for safer, healthier and more prosperous communities. He co-founded Desktop Genetics, which creates artificial intelligence that assists researchers and clinicians using CRISPR in what will eventually be human patients. Perello’s company has emerged as an established leader in the field of genome editing technology, with genome editing experts, data scientists and bioinformaticians in its world-class team.
Rita da Motta Marques, MSc
Rita da Motta Marques is a Senior Customer Success Manager on Microsoft. Currentely, she is a Healthcare Business Industry leader, with a track record of excellence, tripling business growth around the globe, across Healthcare public and private sectors. With competences on technology and business development, Rita da Motta Marques has been driving digital transformation across several geographies to guarantee solid and sustainable results for the organisations.
José Luís Passos Coelho, MD PhD
Professor José Luís Passos Coelho completed his medical degree in the Faculty of Medicine of Lisbon University, specializing in Medical Oncology. He currently dedicates his clinical activity to patients with breast and testicular cancer. He advocates the proximity between clinical practice and basic research in order to allow a more critical advance of scientific knowledge.